Jibran Atwi, MD
Allergy & Immunology · Lafayette, LANPI 1154322923
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Sanofi at 31.6% of the total. 2025 is the largest year on record at $947, 5.1 times the $187 reported in 2019.
Across 184 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$253
- AstraZeneca$201
- Merck$146
- Supernus Pharmaceuticals, Inc.$128
- Takeda Pharmaceuticals U.S.A., Inc.$122
- plus $1K from 29 others
Across 950 payments — averaging $10,186 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$3.1M
- Novavax Inc$2.7M
- GSK$1.5M
- Sanofi US Services Inc.$378K
- Pfizer$360K
- AstraZeneca$312K
- plus $1.4M from 14 others
What the payments were for
- Food & beverage$3,16695%
- Education$1735%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 54 | $1,056 |
| Regeneron Healthcare Solutions, Inc. | 11 | $253 |
| AstraZeneca | 11 | $201 |
| Merck | 9 | $146 |
| Supernus Pharmaceuticals, Inc. | 9 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $122 |
| Pfizer | 10 | $118 |
| CSL Behring | 6 | $112 |
| Biocryst US Sales Co., LLC | 6 | $107 |
| Ironshore Pharmaceuticals Inc. | 6 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Amgen | 4 | $98 |
| GSK | 6 | $97 |
| Sanofi Pasteur Inc. | 5 | $68 |
| Kowa Pharmaceuticals America, Inc. | 3 | $62 |
| LEO Pharma Inc. | 3 | $54 |
| Ionis Pharmaceuticals, Inc. | 2 | $46 |
| Pharming Healthcare, Inc. | 2 | $45 |
| Phadia US Inc. | 2 | $38 |
| Organon | 6 | $38 |
| Sobi, Inc | 2 | $36 |
| Galderma Laboratories, L.p. | 2 | $36 |
| Novartis | 2 | $32 |
| Seqirus USA Inc | 2 | $32 |
| Millicent US Inc | 2 | $30 |
| Global Blood Therapeutics, Inc. | 2 | $24 |
| Greer Laboratories, Inc. | 2 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Biogen | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Corium, LLC | 1 | $4 |
How this compares
$3,339 in reported general payments places this provider in the 55th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 13 | $75,126 |
| XolairOmalizumab | 21 | $57,650 |
| Dupixent SyringeDupilumab | 14 | $51,603 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,292 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,089 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,765 |
| Azelastine Hcl | 39 | $1,580 |
| Montelukast Sodium | 185 | $1,350 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,173 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,147 |
| Fluticasone Propionate | 73 | $1,044 |
| Cyproheptadine Hcl | 11 | $136 |
| Prednisone | 14 | $34 |
| Azithromycin | 11 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $97 | $21,29233 claims |
| AstraZenecaSymbicort | $201 | $5,08915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Lafayette
- Erin PrattLafayette$17K
- Andrew CollinsLafayette$5K
- Alexandra ChastantLafayette$2K
- Bina JosephLafayette$792
- Bernard FrugeLafayette$297
- Elizabeth RobertsonLafayette$14
- David KaufmanShreveport$678K
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
- Brice RolstonCovington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.